Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Leslie Tari Sells 1,773 Shares

Cidara Therapeutics, Inc. (NASDAQ:CDTX) insider Leslie Tari sold 1,773 shares of Cidara Therapeutics stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $21.96, for a total value of $38,935.08. Following the transaction, the insider now owns 16,215 shares of the company’s stock, valued at $356,081.40. The trade was a 9.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Cidara Therapeutics Trading Down 1.4 %

CDTX stock opened at $22.05 on Friday. Cidara Therapeutics, Inc. has a 12-month low of $10.00 and a 12-month high of $28.42. The stock has a market cap of $155.39 million, a price-to-earnings ratio of -0.86 and a beta of 0.88. The business’s 50-day moving average is $22.17 and its 200 day moving average is $17.71.

Cidara Therapeutics (NASDAQ:CDTX) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($5.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.28) by ($0.10). Cidara Therapeutics had a negative return on equity of 69.64% and a negative net margin of 289.05%. As a group, equities analysts forecast that Cidara Therapeutics, Inc. will post -8.74 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on CDTX shares. HC Wainwright lifted their price target on Cidara Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Citizens Jmp started coverage on Cidara Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $46.00 price target for the company. Cantor Fitzgerald upgraded Cidara Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 5th. Royal Bank of Canada started coverage on Cidara Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $34.00 price target for the company. Finally, JMP Securities set a $46.00 price target on Cidara Therapeutics in a research note on Wednesday. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Cidara Therapeutics has an average rating of “Buy” and a consensus price target of $39.14.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cidara Therapeutics during the 4th quarter worth approximately $56,000. Northern Trust Corp boosted its holdings in shares of Cidara Therapeutics by 6.8% during the 4th quarter. Northern Trust Corp now owns 33,957 shares of the biotechnology company’s stock worth $913,000 after purchasing an additional 2,170 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Cidara Therapeutics during the 4th quarter worth approximately $165,000. Geode Capital Management LLC boosted its holdings in shares of Cidara Therapeutics by 22.7% during the 3rd quarter. Geode Capital Management LLC now owns 52,898 shares of the biotechnology company’s stock worth $569,000 after purchasing an additional 9,771 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Cidara Therapeutics during the 4th quarter worth approximately $339,000. 35.82% of the stock is currently owned by institutional investors and hedge funds.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.